Skip to main content

New coronavirus test promises to give you results on an app in 30 minutes

 

A newly developed test from the U.K. could quickly diagnose the coronavirus, officially known as COVID-19, with the help of a smartphone app. 

Recommended Videos

The smart testing device — developed by researchers at Lancaster University, Brunel University in London, and the University of Surrey — could provide results within 30 minutes using a combination of artificial intelligence, image processing, and molecular virology, according to an announcement.

The test could be used by health care workers to test patients, or even allow people to test themselves, researchers said.

The device works like this: Nasal or throat swabs are taken from the patent and inserted into the device, which is synced to a mobile app. Researchers say the app can then control the device, provide telemedicine options, and even track someone’s movement to help contain the spread of the virus.

Researchers are working on ways for the app to alert others if they have come in close contact with someone who has tested positive for coronavirus. 

The device would cost about $120 and could be used to test up to six people. The team behind the research said it is talking with backers to “get it urgently mass-produced.”

“The team firmly believes that both identifying COVID-19 infection and minimizing the spread of infection are important. Once infection is identified using this device, the app will automatically update the database, and the intelligent system will track down all individuals who have been in close contact with the newly identified patient, alert them about the threat of having COVID-19, and make recommendations regard further steps,” said Dr. Anil Fernando of the University of Surrey in a statement. 

Digital Trends reached out to Lancaster University to find out when researchers expect the test to be available for use and purchase. We will update this story when we hear back. 

Testing in the U.S. remains far below levels experts suggest, with advocates like Microsoft co-founder Bill Gates pushing for more testing to identify and contain the rapid spread of the coronavirus.

As of Thursday, more than 463,700 people have been infected, and there have been over 21,100 deaths. The World Health Organization has declared the coronavirus a pandemic, with countries around the globe struggling to deal with the impacts of the crisis.

Allison Matyus
Former Digital Trends Contributor
Allison Matyus is a general news reporter at Digital Trends. She covers any and all tech news, including issues around social…
How to sign up for a coronavirus vaccine trial
Cambridge Biotech Moderna Leads in Race For Coronavirus Vaccine

 

With the race to develop a coronavirus vaccine heating up, clinical studies around the U.S are looking for willing participants to help them complete various stages of their research. Tech conglomerates Moderna, AstraZeneca, Johnson & Johnson, and Novavax are all in various stages of human trials, each of which requires hundreds of volunteers. So how does one sign up for a vaccine trial?
How to sign up for a coronavirus trial
While the words "scientific trial" may bring up images of mad scientists, the average clinical study is an important part of the vaccine development process. After methods prove hopeful in laboratories, researchers then perform several detailed studies with humans, to perfect the product. To speed up trial involvement for a coronavirus vaccine, the U.S. National Institute of Health has launched an online public network that connects possible volunteers with hundreds of research facilities across the U.S.

Read more
Fauci ‘cautiously optimistic’ we will have a coronavirus vaccine this year
gloved hands holding coronavirus test tube stylized image

 

Dr. Anthony Fauci told a House panel he is "cautiously optimistic" that a coronavirus vaccine will be developed this year.

Read more
New coronavirus vaccine triggers immune response in early testing
medical employee holding mask stylized image

 

A coronavirus vaccine developed by Oxford University and drug company AstraZeneca triggered an immune response in early trials, according to a study published on Monday, July 20. 

Read more